The Satcher Health Leadership Institute at Morehouse School of Medicine (SHLI), with support from Otsuka America Pharmaceutical, Inc., a leader in mental health, released The Economic Burden of Mental Health Inequities in the United States Report. SHLI looked at a four-year period (2016-2020) and found, at minimum, nearly 117,000 lives and approximately $278 billion could have been saved. The full report is now available for download.
At the heart of our mission – Otsuka-people creating new products for better health worldwide – is a deep-rooted commitment to improving the lives of people of all races, ethnicities, genders, orientations, disabilities, and many other attributes.
Creating an inclusive, equitable today and tomorrow for our people, patients, and communities.
Otsuka people believe that our current and future success is grounded in science and innovations that are fueled by diversity of lived experiences and thoughts. Our inclusive values inspire unique contributions that lead to new products and health solutions – ultimately enabling equity and access to better outcomes for our people, patients, community, and humanity.
“Otsuka has always believed in the power of inclusion. We will continue to work with intention, purpose, and accountability as we build a more diverse workplace and an equitable, inclusive Otsuka culture where all can thrive today and in the future.”
– Sabrina Mays-Diagne, Senior Director,
Otsuka Diversity, Equity & Inclusion Officer
“We respect diversity in all forms both among individuals and across our entire global workforce, and we encourage the full leveraging of these unique combinations of capabilities.”
– Makoto Inoue, President and Representative
Director Otsuka Pharmaceutical Co., Ltd.
“I have had the pleasure and privilege of working with people across continents, from different cultures and beliefs. Through these humbling experiences I have seen first-hand the beauty that diversity adds to our world. As Otsuka-people, we work hard towards ensuring that more people will come to share this belief each day.”
– Tarek Rabah, President & CEO, Otsuka
North America Pharmaceutical Business
From a prospective employee’s first interaction with Otsuka to an employee’s very last day with the company, we are dedicated to ensuring equal opportunity and a sense of belonging and acceptance for all. Inclusive job descriptions, the recruitment of candidates from diverse professional networks, clear pathways for development and promotion, and employee resource groups, are just some of the ways we put these beliefs into practice.
BeOne is an Otsuka business and employee resource group that serves as an advisor to Otsuka's leadership to ensure meaningful representation by Otsuka’s Black talent across all aspects of Otsuka’s business and philanthropic interests.
We hope to encourage and equip women to continue seeking positions of higher responsibility, enabling more employees to defy limitation, so that others can too. Through networking and educational events, thought provoking content, and certification programs, all Otsuka-people can have the opportunity to enhance their business impact.
Community WELL is Otsuka's peer-to-peer mental wellness group. It is a place for those with and without a diagnosis to share stories and experiences, build community and connection, and reduce stigma and inspire hope within the Otsuka community.
Promotes cultural and heritage awareness of the Asian Pacific Islander (API) community and supports the development and advancement of our members and allies in their career journeys. We strive to enhance Otsuka’s vision and diversity initiatives.
Supports Otsuka in the recruitment and retention of Hispanic/LatinX talent. We provide opportunities for personal and professional development, build relationships, increase awareness and understanding of the variety of our rich cultures, and facilitate development opportunities through networking, workshops, and company events.
Creates an open and inclusive environment where members and allies of the LGBTQIA+ Community feel fully supported and accepted. Through conversation, education, exposure, inquiry, and exchange of ideas, we will increase awareness so that each Otsuka employee can develop an understanding and sense of belonging.
Through partnership, networking, and participation in public and corporate events, we establish Otsuka as a leader in eradicating stigma on behalf of the LGBTQIA+ Community in the workplace.
Overcoming barriers to access to medications and clinical trials is critical to creating an equitable healthcare ecosystem and Otsuka is committed to doing our part to address this need. We are actively working to help patients access support through our Otsuka Patient Support Program and Otsuka Patient Assistance Foundation (OPAF), as well as democratize and increase access to our clinical trials.
A customer-centric support network comprised of dedicated professionals and enhanced digital offerings striving to deliver efficient resolution to questions and challenges.
Otsuka recognizes and greatly benefits from the diverse perspectives, products, and services of women-, LGBTQ+-, veteran-, disability-owned, and other minority-owned, marginalized and/or underrepresented suppliers.
Otsuka will make sourcing decisions based on the best total value offered to supply our requirements for goods and services. Best total value is driven by business needs and financial discipline and is comprised of several components, including total cost of ownership, quality of goods, services performed, supplier’s responsiveness, financial and operational risk, speed or time-to-market, minority/women/veteran/disabled ownership, localized supply, and suppliers’ knowledge of Otsuka.
At Otsuka, we are committed to walking alongside patients and their care partners to identify and invest in innovative solutions that reduce disparities and inequities, and improve their health, well-being and quality of life. To help advance our mission, Otsuka provides support to qualified 501© (3) non-profit organizations and government entities in the form of foundation grants, corporate contributions and sponsorships, product donations and employee giving and volunteerism, focused on:
Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announce positive results of the Phase 3 clinical trial of brexpiprazole in the treatment of agitation in patients with Alzheimer's dementia (NCT03548584). The analysis concluded that there is a statistically significant difference (p=0.0026) in the mean change from baseline to Week 12 in the Cohen-Mansfield Agitation Inventory (CMAI) total score between brexpiprazole and placebo.
Otsuka Pharmaceutical Co., Ltd. announces that it has decided to terminate its global license agreements with Akebia Therapeutics, Inc. for vadadustat (generic name), under development as an oral treatment for anemia associated with chronic kidney disease (renal anemia). These licenses were signed in in December 2016 for the U.S. and April 2017 for Europe and other regions.
At Otsuka, we hold a deep respect for the value of every mind. We will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention for patients and caregivers everywhere.
3 Pillars of Change to Impact the Costs of Mental Illness in the US
Supporting mental health requires multifaceted collaboration
an interview with Tarek Rabah
The Invisible “Industry” of Family Caregiving
by Otsuka
At Otsuka, we hold a deep respect for the value of every mind. We believe that the human mind is infinitely valuable, fostering imagination, intelligence, perception, and so much more. By recognizing this value, we have the power to change the trajectory of people’s lives. This is why we will not rest until mental illnesses and brain diseases are approached with the same priority and urgency as our physical health and recognized as chronic diseases that warrant early, equitable, and accessible intervention. Through products, programs, policies, and advocacy, Otsuka-people will defy any limitation that stands in their way until every mind is valued.
This commitment extends to those who care for people living with mental illnesses and other brain conditions. We are dedicated to caring for those who care for our patients—standing with them, the way they stand with their loved ones—and offering the tools they need for the health of others and themselves.
Otsuka America Pharmaceutical, Inc. hosted its 4th annual Advancing Mental Health Policy Forum on Monday, May 9, 2022 at Hyatt Regency on Capitol Hill. The forum brought together federal and state policymakers as well as key advocacy partners and other experts from the mental health community who are passionate about transforming the way mental illness is treated. Grammy Award-winning singer-songwriter, actress and mental health advocate Michelle Williams, member of Destiny’s Child, served as keynote speaker and shared her personal experience living with depression.
“Otsuka is dedicated to developing breakthrough therapies and contributing to the future of medicine. As a company, we are rooted in our core values of creativity, unconventional thinking and perseverance as we make progress towards our goals. As Otsuka-people, we promise to walk alongside people and their care-partners, strengthening each other as we create solutions and outcomes that matter together. We are honored to devote our corporate lives to serving others.”
Tarek Rabah, President & CEO, Otsuka North America
Pharmaceutical Business, Otsuka Pharmaceutical Co., Ltd.
Otsuka’s Economic and Health Impact in the United States highlights the contributions of Otsuka’s U.S. pharmaceutical subsidiaries — Otsuka America Pharmaceutical, Inc. (OAPI) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Collectively, the subsidiaries comprise nearly 2,000 employees at three corporate offices and other locations in the United States working in all aspects of bringing new medicines to market, from research and development to commercialization.
Otsuka Holdings Co., Ltd. has decided to donate 20 million yen (approximately USD 164,000) through the Japanese Red Cross Society for humanitarian assistance to people whose lives have been severely affected in Ukraine and who have been evacuated to surrounding countries.
In addition, Otsuka Holdings is providing support to patients and people involved in treatment through the provision of Otsuka products, including pharmaceuticals.
Otsuka and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) of REXULTI® (brexpiprazole) for the treatment of schizophrenia in pediatric patients 13 to 17 years of age. The FDA previously granted Priority Review for the sNDA, a designation for a drug application that, if approved, would represent a significant improvement in the safety and/or effectiveness of the treatment, diagnosis, or prevention of a serious medical condition. REXULTI was approved in the U.S. in 2015 for the treatment of schizophrenia in adults and for adjunctive treatment of major depressive disorder in adults.
